Warning Letter — Zap Expo Center Inc.
The FDA issued a Warning Letter to Zap Expo Center Inc. following an evaluation by the Office of Inspections and Investigations.
Zap Expo Center Inc., its management, and regulatory compliance teams within the organization.
The issuance of a Warning Letter signifies that the FDA has identified significant violations of regulatory requirements. This may lead to further enforcement actions, such as seizures or injunctions, if the underlying compliance issues are not remediated to the agency's satisfaction. The source provides limited detail on the specific nature of the violations, but it reinforces the FDA's active oversight of distribution and expo centers.
Review internal compliance protocols regarding FDA-regulated product distribution; ensure that all inventory and marketing materials align with current federal regulations to avoid enforcement actions; monitor for further detailed inspection findings if made available.
FDA Warning Letter issued to: Zap Expo Center Inc.. 03/31/2026 — Office of Inspections and Investigations. Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zap-expo-center-inc-726547-03312026
Open in openFDA / FDA.gov